

SUPPLEMENTARY MATERIAL

Use of Sodium–Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes

Shaline Rao

NYU Langone Medical Center, New York City, NY, USA

Corresponding author:

Shaline Rao, MD

Division of Cardiology, Department of Medicine

NYU Langone Medical Center

530 First Avenue

Skirball 9N

New York, NY 10016, USA

Tel: 646-501-0119; Fax: 646-501-0145

Email: Shaline.Rao@nyulangone.org

Supplementary Table S1. Key ongoing and recently completed (data publication pending)

clinical studies investigating the effect of sodium–glucose cotransporter-2 inhibitors on heart failure outcomes

Study name (Clinical trial identifier)	Patient population	Treatment	Primary outcome	Estimated study completion date
DELIVER (NCT03619213)	HFpEF (<i>n</i> = 4700)	Dapagliflozin vs placebo	Composite of CV death, HHF, or urgent HF visit	January 2022
DAPA ACT HF-TIMI 68 (NCT04363697)	HFrEF (post HF) (<i>n</i> = 2400)	Dapagliflozin vs placebo	Time to CV death or worsening HF	May 2023
Dapagliflozin Heart Failure Readmission (NCT04249778)	HFrEF +/- T2D (post HF) (<i>n</i> = 392)	Dapagliflozin vs placebo	Composite of hospital admissions, ED visits, urgent clinic visits, and death after admission for decompensated HF	December 2023
DAPA-MI (NCT04564742)	HFrEF (post MI) (<i>n</i> = 6400)	Dapagliflozin vs placebo	Composite of HHF or CV death	June 2023
EMPULSE (NCT04157751)	HFrEF or HFpEF (<i>n</i> = 500)	Empagliflozin vs placebo	Composite of death, number of HFE, time to first HFE, and change in KCCQ TSS	Completed (data release pending)
EMPACT-MI (NCT04509674)	Post MI with high risk of HF (<i>n</i> = 3312)	Empagliflozin vs placebo	Composite of time to first HHF or all-cause mortality	December 2022

CV cardiovascular, *DAPA ACT HF-TIMI 68* Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure - Thrombolysis in Myocardial Infarction 68, *DAPA-MI* Dapagliflozin Effects on Cardiovascular Events in Patients with an Acute Heart Attack, *DELIVER* Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure, *ED* emergency department, *EMPACT-MI* Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction), *EMPULSE* A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure, *HF* heart failure, *HFpEF* heart failure with preserved ejection fraction, *HFrEF* heart failure with reduced ejection fraction, *HFE* heart failure event, *HHF* hospitalization for heart failure, *KCCQ TSS* Kansas City Cardiomyopathy Questionnaire Total Symptom Score, *MI* myocardial infarction, *T2D* type 2 diabetes, *vs* versus